Slide 1: Transforming cancer care with the first FDA cleared device for CTC capture and harvest
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells Shares Investor Event 3 September 2024 Andrew Newland and Ian Griffiths
Slide 2: Forward looking statements
LSE AIM:AGL OTCQX:ANPCY Forward looking statements This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be abound by the following conditions. The presentation slides which follow this notice and the oral presentati
Slide 3: ANGLE – transforming cancer care
ANGLE – transforming cancer care Our Mission: Parsortix® instrument FDA INTENDED USE Enable personalised cancer care with a simple blood test to guide treatment, The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich improving patient outcomes and reducing circulating tumor ce
Slide 4: Cancer cases growing rapidly with significant impact on global economies
Cancer cases growing rapidly with significant impact on global economies Estimated number of new cancer cases from 2022-20504 18.7 million new cancer cases p.a. with a further 49.3 million people diagnosed in the previous five years1 77% growth in cancer cases by 2050 with global cancer cases expect
Slide 5: Three major pharma agreements signed 2024 YTD
Three major pharma agreements signed 2024 YTD Global Japanese pharma company • Revenues >£3.8 billion >10,000 employees • >70 active oncology clinical trials >50,000 participants • HER2 targeting antibody-drug conjugate (ADC) being co- There are 12 FDA approved developed by Eisai and Bliss Biopharma
Slide 6: Three major pharma agreements signed 2024 YTD
Three major pharma agreements signed 2024 YTD Global pharma company with major oncology focus contributing to 39% of total product sales1 • 459 active, interventional cancer clinical trials in 139,000 patients • Therapies targeting DNA Damage Response form one of six key " It is through our science-
Slide 7: Three major pharma agreements signed 2024 YTD
Three major pharma agreements signed 2024 YTD AR plays a pivotal role in Androgen Receptor (AR) detection assay for use in prostate cancer, especially castration-resistant prostate AstraZeneca’s prostate cancer studies cancer (CRPC). • 12-month development phase worth £550,000 CRPC is incurable and
Slide 8: Pharma services business
Pharma services business • Assay development and pilot studies c. £200,000 Pharma companion diagnostic pathway - indicative only Revenue Potential Year 1 Phase I £0.2m to £0.7m Years 2-3 Phase II £1.2m to £3.6m Years 4-5 Phase III £15m to £45m Year 6 onwards Companion Diagnostic £20m to £100m per an
Slide 9: Integrated business model to drive industry-wide adoption
Integrated business model to drive industry-wide adoption • Products – Parsortix PC1 system, Parsortix cassettes and controls for clinical use for metastatic breast cancer for user validated assays (clinical) – Parsortix PR1 system and cassettes for research use (RUO) – Portrait+ CTC staining kit in
Slide 10: Differentiated pharma services offering
Differentiated pharma services offering • Customer base established and growing – multiple customers, repeat business Key capabilities: – new customers in 2024 and growing pipeline • Repeat testing before during and after treatment • Significant revenue and profitability potential • Access to live c
Slide 11: Existing and repeat pharma services customers
Existing and repeat pharma services customers Developing cancer treatments targeting DNA Damage Response (DDR) pathways • Bespoke assay development of DDR assay to measure DNA damage on CTCs • Clinical study in advanced solid tumours (Breast, Ovarian, Prostate) Immuno-oncology company developing tar
Slide 12: Growing body of third-party evidence
Growing body of third-party evidence • FDA and EU clearance expected to give ANGLE first mover advantage As of April 2024 in non-invasive repeat testing of intact cancer cells Clinically relevant biomarkers 82% published in including: • >290 Parsortix systems in use EGFR BRAF 38 high impact journals
Slide 13: Strong commercial progress
Strong commercial progress • Pharma services – building high impact pharma business with long term relationships – three commercial agreements with large pharma in 2024 to date – multiple contract discussions in progress • Products – global distribution network – Portrait+ CTC Staining kit launched
Slide 14: ANGLE plc contact details
ANGLE plc 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom angleplc.com © ANGLE plc 2024 14